Health Care
Medicaid, Medicare, drug pricing and public health.
-
Policy Brief
FDA’s Peptide Review Should Include a Hard Look at the Supply Chain
Why regulators must look beyond patient access and weigh the risks of foreign supply chain dependencies.
-
Policy Brief
Government Can’t Reduce Smoking by Attacking Safer Alternatives
New Mexico legislators are considering higher taxes and new restrictions on nicotine products such as nicotine pouches. These proposals are typically framed as public-health measures. In practice, they risk doing precisely the opposite—nudging smokers back toward…
-
Policy Brief
Rural Medicare Advantage Customers See Decreased Options
As the December 7 Medicare Open Enrollment deadline approaches, rural seniors face shrinking coverage options as major insurers scale back Medicare Advantage plans nationwide.
-
Testimony & Comments
SPPI Joins National Coalition Calling for Accountability in the Non-Profit Hospital Sector
“Large nonprofit hospital systems have exploited taxpayer subsidies and regulatory loopholes while failing to deliver the public benefit they promise.”
-
Op-Ed
Don’t waste the windfall; Use opioid settlement funds where they count
America may finally be turning a corner in the opioid crisis. For the first time in years, overdose deaths are declining. The Centers for Disease Control and Prevention recently reported a 17% decrease in opioid-related fatalities…
Originally published inSanta Fe New Mexican
-
Policy Brief
Ensuring Accountability and Impact in Opioid Settlement Spending
The $26 billion opioid settlement offers a once-in-a-generation opportunity to combat America’s deadliest drug crisis, if states and localities spend the funds transparently, strategically, and solely on opioid abatement.
-
Policy Brief
Is the CFPB Paving the Way for Single-Payer Healthcare Through Medical Debt Reform?
The CFPB’s recent modifications to medical debt reporting may be subtly steering the U.S. toward a single-payer healthcare system by minimizing the visibility of medical debt.
-
Op-Ed
Excessive regulation is fueling a health care crisis in Utah
Recent research has shown that health care consolidations not only lower costs for health care consumers but also improve multiple indicators of quality patient care.
Originally published inDeseret News
-
Op-Ed
The high cost of prescription drug price controls
Components of the Inflation Reduction Act have the very real potential of inflating drug prices with arbitrary price controls. Consumers will pay the price.
Originally published inThe Washington Times